GC Wellbeing is officially entering the botulinum toxin market.
GC Wellbeing noted on the 12th that it has acquired equity that includes management rights from the aesthetic corporation Inivio.
With this equity acquisition, GC Wellbeing will hold 1,272,250 shares, which is 21.4% of Inivio's equity. The purchase amount for the equity is approximately 40 billion won.
GC Wellbeing is officially entering the botulinum toxin market through the acquisition of Inivio. Inivio possesses the botulinum toxin "Inivo." Inivo is free from sourcing controversies as it introduced botulinum toxin strains from the CCUG, a microbial supply agency and strain bank in Sweden.
Inivio has established long-term supply contracts with seven countries worldwide and has been expanding its overseas network. GC Wellbeing plans to leverage Inivio's overseas network to target the global botulinum toxin market. The size of the global botulinum toxin market is expected to grow from approximately 12 trillion won last year to around 31 trillion won by 2030.